Crinetics Pharmaceuticals
CRNX
122 hedge funds and large institutions have $993M invested in Crinetics Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 45 increasing their positions, 37 reducing their positions, and 13 closing their positions.
115% more call options, than puts
Call options by funds: $43K | Put options by funds: $20K
22% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 37
5.79% more ownership
Funds ownership: 96.05% → 101.83% (+5.8%)
5% more capital invested
Capital invested by funds: $948M → $993M (+$45.1M)
0% more funds holding
Funds holding: 122 → 122 (0)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
0% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FC
Finepoint Capital
Boston,
Massachusetts
|
+$14.5M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$6.53M |
| 3 |
Millennium Management
New York
|
+$4.47M |
| 4 |
State Street
Boston,
Massachusetts
|
+$3.46M |
| 5 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$3.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$22.6M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$16.6M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$14.4M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$14.1M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$2.8M |
CRNX Hedge Fund Activity: Q4 2022 in Review
122 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q4 2022, worth a combined $993M — up 4.8% from $948M a quarter earlier.
Fund positioning in CRNX was balanced in Q4 2022: 13 funds opened new positions, 13 closed out, 45 added to existing stakes and 37 trimmed.
The largest buyer was Finepoint Capital, opening a new position worth an estimated $14.5M. The largest seller was Perceptive Advisors, cutting an estimated $22.6M.
- 122 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $993M of Crinetics Pharmaceuticals stock for Q4 2022, up 4.8% quarter-over-quarter.
- 13 funds opened new Crinetics Pharmaceuticals positions in Q4 2022 and 13 closed out, a net change of 0 holders.
- The largest Crinetics Pharmaceuticals buyer in Q4 2022 was Finepoint Capital, an estimated $14.5M added.
- The largest Crinetics Pharmaceuticals seller in Q4 2022 was Perceptive Advisors, an estimated $22.6M sold.
Based on aggregated 13F filings for Q4 2022.